Opus Genetics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Opus Genetics, Inc. on August 29, 2025. The report discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Annual Base Salary: $465,000
- Performance Bonus: Up to 45% of annual base salary
- Stock Options: 250,000 shares
- Stock Awards: 200,000 shares (under the 2021 Inducement Plan)
- Vesting Period: Four years for both equity grants
Material Changes
The primary material change is the appointment of Robert Gagnon as Chief Financial Officer and principal accounting officer, effective September 2, 2025. This represents a change in senior management leadership.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of Mr. Gagnon's appointment and his professional background. No specific financial guidance, outlook, or new risk factors were disclosed in this filing. Mr. Gagnon brings prior experience as CFO of Remix Therapeutics, Verastem, Inc., and Harvard Bioscience, Inc., as well as an Operating Partner role at Gurnet Point Capital.
Key Facts for Investor Verification
- Verify the effective date of the CFO appointment (September 2, 2025).
- Review the full Employment Agreement (Exhibit 10.1) for specific vesting schedules and termination provisions.
- Confirm the total potential equity value based on the current trading price of IRD stock.
- Check for any prior disclosures regarding the departure of the previous CFO.